Kyowa Kirin pits mogamulizumab against vorinostat in new US PhIII trial for CTCL
This article was originally published in Scrip
Executive Summary
Building on recently reported positive Phase IIb Japanese data for the first-in-class antibody in the indication, Kyowa Hakko Kirin has initiated a Phase III US trial with mogamulizumab for the treatment of cutaneous T-cell lymphoma (CTCL).